sample size for partial replicate - USFDA [Power / Sample Size]

posted by niraj.bhatt – India, 2013-10-18 10:18 (4628 d 16:04 ago) – Posting: # 11688
Views: 17,289

Dear John,

Thank you for your reply.

I have found a paper "Tothfalusi & Endrenyi. Sample Sizes for Designing Bioequivalence Studies for Highly Variable Drugs. J Pharm Pharmaceut Sci. 15(1) 73-84, 2012".

Suppose within-subject variability for reference formulation in 3 -period partial replicate study was found 30%.

Then as per above paper, sample size for 3 -period partial replicate pivotal study, intended for USFDA submission, is 24 subjects for GMR of 0.95 to acheive at least 80% power for within-subject variability of reference formulation of 30% (as per page 11 of 12 from above paper).

I am looking forward your suggestion for my understanding.

Best regards.
Niraj

Complete thread:

UA Flag
Activity
 Admin contact
23,655 posts in 4,993 threads, 1,570 registered users;
121 visitors (0 registered, 121 guests [including 24 identified bots]).
Forum time: 02:22 CEST (Europe/Vienna)

Science is simply common sense at its best that is,
rigidly accurate in observation, and
merciless to fallacy in logic.    Thomas Henry Huxley

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5